易緯集團(03893.HK)年度虧損淨額約2190萬港元
格隆匯9月27日丨易緯集團(03893.HK)發佈公吿,截至2022年6月30日止年度,公司收入、毛利及虧損淨額分別約為4000萬港元、約1170萬港元及約2190萬港元,較上年度分別減少約53.8%、37.4%及增加約85.6%。
集團的綜合虧損淨額增加,是因為(i)集團的收入及毛利因上述2019冠狀病毒病疫情蔓延情況所導致的艱難局面以及全球經濟面對的衰退威脅增加而減少;及(ii)2019冠狀病毒病疫情爆發後,經濟環境轉差及集團的業務前景不明朗,於本年度確認集團若干物業、廠房及設備的減值虧損約330萬港元(2021年:無)所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.